Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported first-quarter 2026 financial results, highlighting continued commercial momentum for TONMYA, its recently launched fibromyalgia treatment, and advancement across its clinical pipeline. TONMYA, the first new fibromyalgia medicine in 15 years, has shown growth in prescriptions, prescribers, refills and patient access since its November 2025 launch. The company noted a recently announced managed care agreement that expands potential coverage to approximately 35 million U.S. commercial lives.
Pipeline progress included positive Phase 1 data for TNX-4800, a Lyme disease prevention candidate, and plans to begin a Phase 2 study of TONMYA in major depressive disorder later this year. Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years.
Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The positive Phase 1 data for TNX-4800 represents a significant step toward addressing Lyme disease, a growing public health concern. If approved, it could provide a prophylactic option for individuals at risk of tick bites. Furthermore, the planned Phase 2 study of TONMYA in major depressive disorder could expand the drug's indications, potentially benefiting patients who have not responded to existing treatments. The managed care agreement for TONMYA, expanding coverage to millions of commercial lives, may improve patient access to a novel fibromyalgia therapy that has been unavailable for over a decade.
Tonix’s pipeline also includes TNX-1500, which targets prevention of kidney transplant rejection, addressing a critical need in transplant medicine. The company’s focus on CNS and immunology areas with high unmet medical need positions it to make meaningful impacts on patient care. As Tonix continues to execute on its commercial and clinical strategies, stakeholders will be watching for further updates on prescription trends and trial results. The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP.
The full press release can be found at https://ibn.fm/oVPHY.
